Holen Sie sich die Stockscreener-App
25.85
2.60%
-0.69
Handel nachbörslich:
25.85
Zenas Biopharma Inc Aktie (ZBIO) Neueste Nachrichten
Nunn Jason Raleigh buys Zenas Biopharma (ZBIO) shares worth $1.2 million - Investing.com
Sr One Capital buys Zenas Biopharma (ZBIO) shares worth $2.4 million - Investing.com
Should you wait for a breakout in Zenas BioPharma Inc.2025 Market Overview & Long-Term Growth Portfolio Plans - newser.com
Risk vs reward if holding onto Zenas BioPharma Inc.Market Performance Summary & Low Risk Investment Opportunities - newser.com
Zenas BioPharma rises after Wedbush raises price target - MSN
Zenas gets global rights for Innocare BTK inhibitor in $2B+ deal - BioWorld MedTech
Enright buys Zenas Biopharma (ZBIO) stock worth $2.25 million - Investing.com
Zenas climbs on licensing deal with InnoCare - MSN
Will Zenas BioPharma Inc. stock benefit from AI adoptionJuly 2025 Decliners & Consistent Return Strategy Ideas - newser.com
How Zenas BioPharma Inc. stock reacts to inflationary pressuresJuly 2025 WrapUp & Real-Time Volume Trigger Notifications - newser.com
Strategies to average down on Zenas BioPharma Inc.July 2025 Sector Moves & Risk Managed Trade Strategies - newser.com
What to expect from Zenas BioPharma Inc. in the next 30 daysPortfolio Gains Summary & Risk Managed Investment Entry Signals - newser.com
How to build a dashboard for Zenas BioPharma Inc. stockPortfolio Gains Report & Safe Swing Trade Setups - newser.com
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Zenas BioPharma Independent Director Acquires 447% More Stock - simplywall.st
Zenas BioPharma (ZBIO): Assessing Valuation Following $2B InnoCare Deal and Pipeline Expansion - Sahm
Zenas Biopharma stock hits all-time high at 29.29 USD By Investing.com - Investing.com Canada
Insider Buying: Zenas BioPharma (NASDAQ:ZBIO) Insider Buys 36,928 Shares of Stock - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Director Hongbo Lu Purchases 263,160 Shares - MarketBeat
Fairmount Funds Management Llc Acquires 316,219 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock - MarketBeat
Zenas Biopharma stock hits all-time high at 29.29 USD - Investing.com India
Zenas BioPharma (ZBIO) Is Up 32.5% After Securing Global Rights to Orelabrutinib in MS Deal - Yahoo Finance
Zenas BioPharma (NASDAQ:ZBIO) Sets New 1-Year High Following Analyst Upgrade - MarketBeat
Zenas BioPharma Inc Stock Analysis and ForecastSector Rotation Strategies & Watch Expert Picks Before They Rally - earlytimes.in
Will Zenas BioPharma Inc. stock go up soonTrade Entry Summary & Scalable Portfolio Growth Ideas - newser.com
Wedbush Issues Positive Forecast for Zenas BioPharma (NASDAQ:ZBIO) Stock Price - MarketBeat
HC Wainwright Reiterates Buy Rating for Zenas BioPharma (NASDAQ:ZBIO) - MarketBeat
Zenas BioPharma files automatic mixed securities shelf - MSN
Zenas BioPharma: Strategic Licensing and Clinical Advancements Justify Buy Rating - TipRanks
Rx Rundown: Novo Nordisk, Chiesi Group, Zenas Biopharma and more - Medical Marketing and Media
Zenas Biopharma (ZBIO) director Moulder buys $770k in shares By Investing.com - Investing.com South Africa
InnoCare Pharma: Obutinib signs licensing agreement with Zenas BioPharma - iHeart
Insider Buying Spree: Zenas BioPharma Executives Make Bold Moves! - TipRanks
Zenas Biopharma (ZBIO) director Moulder buys $770k in shares - Investing.com
Lu Hongbo buys Zenas Biopharma (ZBIO) shares worth $6m By Investing.com - Investing.com South Africa
Lu Hongbo buys Zenas Biopharma (ZBIO) shares worth $6m - Investing.com
Zenas BioPharma hits record high as brokerages raise PT - TradingView
Zenas acquires BTK inhibitor in Phase 3 trials for progressive MS - Multiple Sclerosis News Today
Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal (ZBIO) - Seeking Alpha
H.C. Wainwright maintains Zenas Biopharma stock Buy rating on pipeline expansion - Investing.com Canada
Strategic Expansion and Financial Strength Bolster Zenas BioPharma’s Growth Potential: Buy Rating Reaffirmed - TipRanks
Wedbush Raises Price Target on Zenas BioPharma to $40 From $35, Keeps Outperform Rating - MarketScreener
Zenas BioPharma (Nasdaq:ZBIO) Secures License for Three Autoimmune Candidates Including Orelabrutinib - Kalkine Media
Why Zenas BioPharma (ZBIO) Jumped 17.1% After Announcing $200M Shelf Filing and Major License Talks - simplywall.st
Zenas BioPharma and InnoCare Pharma Announce License - GlobeNewswire
Zenas Biopharma Inc Files For Mixed Shelf- SEC Filing - TradingView
Zenas Looks To Target Progressive Multiple Sclerosis Via InnoCare Deal - insights.citeline.com
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):